William D Baird Iii 2seventy Bio, Inc. (TSVT) insider trading activity

William D Baird Iii is President and CEO of 2seventy bio, Inc.. Currently has a direct ownership of 0 shares of TSVT, which is worth approximately $0. The most recent transaction as insider was on May 13, 2025, when has been sold 118,209 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

William D Baird III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 13 2025	SELL Disposition due to a tender of shares in a change of control transaction	-	118,209 Reduced 100.0%	0 Common Stock
May 13 2025	SELL Sale (or disposition) back to the issuer	-	1,002,825 Reduced 89.46%	118,209 Common Stock
Mar 17 2025	SELL Open market or private sale	$25,205 $4.95 p/Share	5,092 Reduced 0.45%	1,121,034 Common Stock
Jan 06 2025	SELL Open market or private sale	$2,121 $2.78 p/Share	763 Reduced 0.09%	862,126 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	264,000 Added 18.99%	1,126,126 Common Stock
Jan 03 2025	SELL Open market or private sale	$93,250 $2.94 p/Share	31,718 Reduced 3.55%	862,889 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	586,022 Added 39.58%	894,607 Common Stock
Apr 01 2024	BUY Grant, award, or other acquisition	-	56,250 Added 15.42%	308,585 Common Stock
Jan 08 2024	BUY Grant, award, or other acquisition	-	91,000 Added 26.5%	252,335 Common Stock
Jan 05 2024	SELL Open market or private sale	$5,175 $3.75 p/Share	1,380 Reduced 0.85%	161,335 Common Stock
Jan 03 2024	SELL Open market or private sale	$130,229 $3.87 p/Share	33,651 Reduced 17.14%	162,715 Common Stock
Aug 22 2023	SELL Open market or private sale	$38,600 $5.49 p/Share	7,031 Reduced 3.46%	196,366 Common Stock
Aug 03 2023	SELL Open market or private sale	$42,333 $6.13 p/Share	6,906 Reduced 3.28%	203,397 Common Stock
Feb 13 2023	SELL Open market or private sale	$8,191 $12.86 p/Share	637 Reduced 0.3%	210,303 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	132,143 Added 38.52%	210,940 Common Stock
Jan 11 2023	SELL Open market or private sale	$11,448 $10.63 p/Share	1,077 Reduced 1.35%	78,797 Common Stock
Jan 09 2023	SELL Open market or private sale	$33,283 $10.33 p/Share	3,222 Reduced 3.88%	79,874 Common Stock
Aug 05 2022	SELL Open market or private sale	$67,387 $16.23 p/Share	4,152 Reduced 4.76%	83,096 Common Stock
Jul 15 2022	SELL Open market or private sale	$56,345 $13.81 p/Share	4,080 Reduced 4.47%	87,248 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	33,750 Added 26.98%	91,328 Common Stock
Feb 17 2022	SELL Open market or private sale	$6,311 $14.78 p/Share	427 Reduced 0.74%	57,578 Common Stock
Jan 07 2022	SELL Open market or private sale	$21,423 $23.91 p/Share	896 Reduced 1.52%	58,005 Common Stock
Nov 11 2021	BUY Grant, award, or other acquisition	-	56,226 Added 48.84%	58,901 Common Stock

Also insider at

BLUE

bluebird bio, Inc. Healthcare

Chief Financial Officer

AXLA

Axcella Health Inc. Healthcare

Director

WDB